Literature DB >> 4012198

[Scintigraphic imaging of benign and malignant tumors of the sympathetic nervous system with meta-iodobenzylguanidine].

B Kimmig, W E Brandeis, M Eisenhut, B Bubeck, P Georgi.   

Abstract

The authors report on their experiences with metaiodine-benzylguanidine (MIBG) scintiscanning in a total of 36 patients. 7 of these patients had a benign pheochromocytoma, 4 a malignant one; neuroblastoma was seen in 10 patients. Scintiscan diagnosis was supplemented by measurements of irradiation exposure and attainable tumour dose. It was also shown that it is possible to mark neuroblastoma cells in cultures. The results of these studies are discussed and compared with those of other working groups. If the physiological pattern of distribution is taken into consideration, and if the proper imaging technique is adopted, MIBG scintiscan is a sensitive and highly specific method in diagnosing pheochromocytomas and neuroblastomas.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4012198

Source DB:  PubMed          Journal:  Rontgenblatter        ISSN: 0300-8592


  3 in total

Review 1.  Paediatric nuclear medicine.

Authors:  A Piepsz; I Gordon; K Hahn
Journal:  Eur J Nucl Med       Date:  1991

Review 2.  123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Authors:  Gitta Bleeker; Godelieve A M Tytgat; Judit A Adam; Huib N Caron; Leontien C M Kremer; Lotty Hooft; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29

3.  Uptake and release of iodine-labelled m-iodobenzylguanidine in a neuroblastoma cell culture system and its importance in neuroblastoma therapy.

Authors:  V Paffenholz; U Ebener; B Kornhuber
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.